← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Glucose Variability

Evidence related to Glucose Variability.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/glucose-variability

Executive Summary

Glucose Variability evidence appears to center on Exenatide.

Among 43 indexed studies and 36 interventions, the strongest signals are summarized from the available evidence. Hybrid closed-loop system has been studied often, while Exenatide appears to have stronger current evidence signals.

  • No strong consistent positive evidence pattern was detected.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
43
Evidence relationships
51
Interventions
36
Outcomes
4
Strong evidence signals
1
Mixed evidence areas
1

Key Findings

  1. 01

    Across 4 studies, Hybrid closed-loop system shows a evidence signal for Glucose variability.

  2. 02

    Across 2 studies, Acarbose shows a moderate positive signal for Coefficient of variation.

  3. 03

    Across 2 studies, Sitagliptin shows a consistent moderate positive signal for Coefficient of variation.

  4. 04

    Across 2 studies, Acarbose shows a consistent moderate positive signal for Mean amplitude of glycemic excursions (MAGE).

Question Highlights

Which interventions have evidence across glucose-variability measures?

Acarbose, Basic carbohydrate counting (BCC), and Exenatide are among the most studied approaches for glucose-variability measures.

Hybrid closed-loop system, Exenatide, and Acarbose are among the best-supported options in the available evidence across 43 studies.

Read the full answer

Acarbose vs Basic carbohydrate counting (BCC) for glucose-variability measures?

Acarbose and Basic carbohydrate counting (BCC) have available evidence for glucose-variability measures, but the comparison requires review of the underlying studies.

Evidence is available for both Acarbose and Basic carbohydrate counting (BCC); the underlying studies are needed for a direct comparison.

Some evidence reported benefits while other evidence found little or no effect.

Read the full answer

Does Exenatide improve mean amplitude of glycemic excursions (MAGE)?

Exenatide appears to improve mean amplitude of glycemic excursions (MAGE).

Moderate evidence is based on 2 supporting studies.

Only a small number of supporting studies are available.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

No strong consistent positive evidence pattern was detected.

Interpretation

The current evidence does not yet show a clear consistent-benefit pattern.

Leading examples

Exenatide · Sitagliptin

Evidence basis: 2 evidence pairs - 4 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Hybrid closed-loop system is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Hybrid closed-loop system · Acarbose · Low-carbohydrate diet

Evidence basis: 10 evidence pairs - 15 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Acarbose may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Acarbose · Exenatide · Sitagliptin

Evidence basis: 8 evidence pairs - 9 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—